Page 1 | Search Results | Blood Advances | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study

Bhavana Bhatnagar, Jessica Kohlschmidt, Shelley J. Orwick, Daelynn R. Buelow, Sydney Fobare, Christopher C. Oakes, Jonathan E. Kolitz, Geoff Uy, Wendy Stock, Bayard L. Powell, Deedra Nicolet, Erin K. Hertlein, Krzysztof Mrózek, James S. Blachly, Ann-Kathrin Eisfeld, Sharyn D. Baker, John C. Byrd

Blood Adv (2023) 7 (16): 4671–4675.

https://doi.org/10.1182/bloodadvances.2023010482

Published: 2023

Includes: Supplemental data

Journal Articles

Association of social deprivation with survival in younger adult patients with AML: an Alliance study

Blood Adv (2023) 7 (15): 4019–4023.

https://doi.org/10.1182/bloodadvances.2022009325

Published: 2023

Includes: Supplemental data

Journal Articles

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation

Marius Bill, Madlen Jentzsch, Lara Bischof, Jessica Kohlschmidt, Juliane Grimm, Laura Katharina Schmalbrock, Donata Backhaus, Dominic Brauer, Karoline Goldmann, Georg-Nikolaus Franke, Vladan Vucinic, Dietger Niederwieser, Alice S. Mims, Uwe Platzbecker, Ann-Kathrin Eisfeld, Sebastian Schwind

Blood Adv (2023) 7 (3): 436–444.

https://doi.org/10.1182/bloodadvances.2021005789

Published: 2023

Includes: Supplemental data

Journal Articles

High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML

Blood Adv (2022) 6 (19): 5570–5581.

https://doi.org/10.1182/bloodadvances.2022007544

Published: 2022

Includes: Supplemental data

Journal Articles

Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia

Zachary D. Epstein-Peterson, Andriy Derkach, Susan Geyer, Krzysztof Mrózek, Jessica Kohlschmidt, Jae H. Park, Sridevi Rajeeve, Eytan M. Stein, Yanming Zhang, Harry Iland, Lynda J. Campbell, Richard A. Larson, Xavier Poiré, Bayard L. Powell, Wendy Stock, Richard M. Stone, Martin S. Tallman

Blood Adv (2022) 6 (11): 3433–3439.

https://doi.org/10.1182/bloodadvances.2021006682

Published: 2022

Journal Articles

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia

Sydney Fobare, Jessica Kohlschmidt, Hatice Gulcin Ozer, Krzysztof Mrózek, Deedra Nicolet, Alice S. Mims, Ramiro Garzon, James S. Blachly, Shelley Orwick, Andrew J. Carroll, Richard M. Stone, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, Christopher C. Oakes, Ann-Kathrin Eisfeld, Erin Hertlein, John C. Byrd

Blood Adv (2022) 6 (5): 1371–1380.

https://doi.org/10.1182/bloodadvances.2021006242

Published: 2022

Includes: Supplemental data

Journal Articles

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Blood Adv (2021) 5 (13): 2775–2787.

https://doi.org/10.1182/bloodadvances.2021004233

Published: 2021

Includes: Supplemental data

Journal Articles

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

Blood Adv (2021) 5 (10): 2481–2489.

https://doi.org/10.1182/bloodadvances.2020003605

Published: 2021

Includes: Supplemental data

Journal Articles

Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia

Christopher J. Walker, Krzysztof Mrózek, Hatice Gulcin Ozer, Deedra Nicolet, Jessica Kohlschmidt, Dimitrios Papaioannou, Luke K. Genutis, Marius Bill, Bayard L. Powell, Geoffrey L. Uy, Jonathan E. Kolitz, Andrew J. Carroll, Richard M. Stone, Ramiro Garzon, John C. Byrd, Ann-Kathrin Eisfeld, Albert de la Chapelle, Clara D. Bloomfield

Blood Adv (2021) 5 (5): 1474–1482.

https://doi.org/10.1182/bloodadvances.2020003727

Published: 2021

Includes: Supplemental data

Journal Articles

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801

Guido Marcucci, Susan Geyer, Kristina Laumann, Weiqiang Zhao, Donna Bucci, Geoffrey L. Uy, William Blum, Ann-Kathrin Eisfeld, Timothy S. Pardee, Eunice S. Wang, Wendy Stock, Jonathan E. Kolitz, Jessica Kohlschmidt, Krzysztof Mrózek, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson

Blood Adv (2020) 4 (4): 696–705.

https://doi.org/10.1182/bloodadvances.2019000492

Published: 2020

Journal Articles

Clinical and functional significance of circular RNAs in cytogenetically normal AML

Blood Adv (2020) 4 (2): 239–251.

https://doi.org/10.1182/bloodadvances.2019000568

Published: 2020

Includes: Supplemental data

Journal Articles

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)

Blood Adv (2018) 2 (24): 3608–3617.

https://doi.org/10.1182/bloodadvances.2018023689

Published: 2018

Includes: Supplemental data

Journal Articles

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission

Sumithira Vasu, Jessica Kohlschmidt, Krzysztof Mrózek, Ann-Kathrin Eisfeld, Deedra Nicolet, Lisa J. Sterling, Heiko Becker, Klaus H. Metzeler, Dimitrios Papaioannou, Bayard L. Powell, Jonathan E. Kolitz, Joseph O. Moore, Maria R. Baer, Gail J. Roboz, Richard M. Stone, John C. Byrd, Andrew J. Carroll, Clara D. Bloomfield

Blood Adv (2018) 2 (13): 1645–1650.

https://doi.org/10.1182/bloodadvances.2017015222

Published: 2018

Includes: Supplemental data

NARROW

Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study

Association of social deprivation with survival in younger adult patients with AML: an Alliance study

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation

High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML

Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801

Clinical and functional significance of circular RNAs in cytogenetically normal AML

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only